Retinitis Pigmentosa clinical trials at UCSD
3 in progress, 0 open to eligible people
OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
Sorry, not currently recruiting here
This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP. This is a multicenter, assessor blinded and randomized study which will enroll 150 subjects.
La Jolla, California and other locations
Single, Intravitreal Injection of 8.8M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
Sorry, not currently recruiting here
This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 8.8 million (8.8M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatment group (8.8M jCell) compared to sham-treated controls.
San Diego, California and other locations
OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
Sorry, in progress, not accepting new patients
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects Investigators will also conduct a Natural History Study (OCU400-104)i This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 24 subjects in the OCU400-101 and 100 subjects in the OCU400-104 study.
La Jolla, California and other locations
Our lead scientists for Retinitis Pigmentosa research studies include Shyamanga Borooah, MD.
Last updated: